FDA Nod for Merck's Grastek

Zacks

Merck & Co. Inc. (MRK) announced that the U.S. Food and Drug Administration (:FDA) has approved Grastek (timothy grass pollen allergen extract), a sublingual tablet for the treatment of Timothy or cross-reactive grass pollen-induced allergic rhinitis with or without conjunctivitis in patients aged between 5 and 65 years.

The approval was not unexpected considering that in Dec 2013 the FDA’s Allergenic Products Advisory Committee had a positive discussion on Grastek.

However, Grastek’s label will include a boxed warning regarding severe allergic reactions associated with the drug. Additionally, the product is also contraindicated in several patient populations including those with severe, unstable or uncontrolled asthma, with a history of any severe systemic allergic reaction and history of any severe local reaction after taking any sublingual allergen immunotherapy and a history of eosinophilic esophagitis.

Grastek, the only FDA approved sublingual allergy immunotherapy tablet for children as young as 5 years old, provides an alternative treatment to patients with allergic rhinitis with or without conjunctivitis, caused by Timothy or cross-reactive grass pollens

Merck has several allergy candidates in advanced stages of development. One of the most advanced candidates, currently under FDA review, is Ragwitek (ragweed pollen allergy). A response should be out in the first half of 2014.

Merck currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Alexion Pharmaceuticals, Inc. (ALXN), Regeneron Pharmaceuticals, Inc. (REGN) and Amgen Inc. (AMGN). While Regeneron and Amgen carry a Zacks Rank #1 (Strong Buy), Alexion holds a Zacks Rank #2 (Buy).

Read the Full Research Report on ALXN
Read the Full Research Report on REGN
Read the Full Research Report on AMGN
Read the Full Research Report on MRK


Zacks Investment Research

Rates

View Comments (0)